Seventy-eight patients undergoing coronary artery bypass grafting (CABG) were compared retrospectively to evaluate whether pretreatment with coenzyme Ql0 (CoQ) is effective in preventing left ventricular depression in early reperfusion following CABG. CoQ (5 mg/kg, intravenously) was given to 60 pat
Coenzyme Q10 and coronary artery disease
β Scribed by Hanakit, Y. ;Sugiyama, S. ;Ozawa, T. ;Ohno, M.
- Publisher
- Springer-Verlag
- Year
- 1993
- Tongue
- English
- Weight
- 341 KB
- Volume
- 71
- Category
- Article
- ISSN
- 1432-1440
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Coenzyme Q 10 (CoQ 10 ) is an essential electron carrier in the mitochondrial respiratory chain and an important antioxidant. Deficiency of CoQ 10 is a clinically and molecularly heterogeneous syndrome, which, to date, has been found to be autosomal recessive in inheritance and generally responsive
## Abstract We performed a 6βmonth openβlabel trial to evaluate the tolerability and efficacy of coenzyme Q10 (CoQ) in 10 patients with Huntington's disease (HD), Subjects were evaluated at baseline, 3 months, and 6 months using the HD Rating Scale (HDRS), the HD Functional Capacity Scale (HDFCS),
## Abstract A practical, highly stereoselective tenβstep synthesis of coenzyme Q~10~ (**1**) has been accomplished (overall yield __ca.__ 28%), starting from commercially available 2,3βdimethoxyβ5βmethylbenzoquinone (__Scheme__). The introduction of the first sideβchain isoprenyl group with (__E__)